Pulmonary Arterial Hypertension Epidemiology Forecast 2025-2034

Pulmonary arterial hypertension (PAH) is a vascular condition marked by elevated pressure and reduced blood flow through the pulmonary arteries, which can ultimately lead to right heart failure and death. As per the Global Burden of Disease (GBD) study of 2021, it has been reported that around 2.28 cases per 100,000 people are affected by PAH every year worldwide.

Pulmonary Arterial Hypertension Epidemiology Forecast Report Coverage

The “Pulmonary Arterial Hypertension Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of pulmonary arterial hypertension. It projects the future incidence and prevalence rates of pulmonary arterial hypertension across various populations. The study covers age, gender, and type as major determinants of the pulmonary arterial hypertension-affected population. The report highlights patterns in the prevalence of pulmonary arterial hypertension over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of pulmonary arterial hypertension in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Pulmonary Arterial Hypertension Disease Overview

Pulmonary arterial hypertension (PAH) is a serious and progressive condition that causes high blood pressure in the arteries connecting the heart to the lungs. This occurs when the pulmonary arteries become narrowed, thickened, or stiff, increasing resistance to blood flow and putting strain on the right side of the heart. Over time, the heart’s ability to pump blood efficiently declines, leading to symptoms such as shortness of breath, fatigue, chest discomfort, and swelling in the legs or abdomen. PAH is a rare disorder that can develop independently or alongside other conditions, such as connective tissue diseases, congenital heart defects, or chronic liver disorders. Without intervention, it can worsen, eventually causing right heart failure and posing significant risks to life.

Pulmonary Arterial Hypertension Treatment Overview

Pulmonary arterial hypertension (PAH) treatment aims to reduce pulmonary artery pressure, improve heart function, and enhance quality of life. Common medications include prostacyclin analogs (e.g., epoprostenol) to dilate blood vessels, endothelin receptor antagonists (e.g., bosentan) to block harmful vascular constriction, and phosphodiesterase-5 inhibitors (e.g., sildenafil) to relax the pulmonary arteries. Oxygen therapy may be prescribed to maintain adequate oxygen levels, and diuretics can help manage fluid retention. In advanced cases, surgical options such as atrial septostomy (creating a small hole between the heart's upper chambers) or lung transplantation may be necessary. Treatment plans are tailored based on disease progression and patient needs.

Epidemiology

The pulmonary arterial hypertension epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for pulmonary arterial hypertension by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for pulmonary arterial hypertension and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The Global Burden of Disease Study 2021 estimated the occurrence of approximately 192,000 prevalent cases of pulmonary arterial hypertension (PAH) worldwide, with females accounting for 62% of cases and males representing 38%.
• It has been reported in studies that patients aging between 75-79 years are most prevalent to develop pulmonary arterial hypertension (PAH). Around 7.99 per 100,000 cases reported are aged 75 years or above.
• It has been addressed that in 2021 around 22,000 deaths were caused due to PAH globally which estimates around 0.27 deaths per 100,000 people.
• Some studies have suggested that the 5-year survival rate for pulmonary arterial hypertension is around 77% for individuals aged 40 years and above.

Country-wise Pulmonary Arterial Hypertension Epidemiology

The pulmonary arterial hypertension epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of pulmonary arterial hypertension varies between countries owing to the differences in factors such as obesity, dietary habits, genetic predisposition, and access to healthcare. Some studies reported that in the United States, pulmonary arterial hypertension (PAH) occurs at an incidence of approximately 2-6 cases per million people annually, with a rising mortality rate associated with the condition each year in the country.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Pulmonary Arterial Hypertension based on several factors.
• Pulmonary Arterial Hypertension Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of pulmonary arterial hypertension are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of pulmonary arterial hypertension epidemiology in the 8 major markets?
• What will be the total number of patients with pulmonary arterial hypertension across the 8 major markets during the forecast period?
• What was the country-wise prevalence of pulmonary arterial hypertension in the 8 major markets in the historical period?
• Which country will have the highest number of pulmonary arterial hypertension patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of pulmonary arterial hypertension during the forecast period of 2025-2034?
• What are the currently available treatments for Pu pulmonary arterial hypertension?
• What are the disease risks, signs, symptoms, and unmet needs of pulmonary arterial hypertension?

This product will be delivered within 3-5 business days.